Skip to content
Screener

Climb Bio, Inc. CLYM Q2 2025 earnings

Reported August 12, 2025 · Before market open

EPS-$0.13Beat by $0.06
EPS estimate-$0.19

Next report

Nov 11, 2026 (in 2 months)
EPS estimate-$0.19

Financials

Q2 2025

Income statement

See full
Operating income-$10.7M+81.1%
Net income-$8.7M+84.2%
EPS (diluted)-$0.13+92.8%

Balance sheet

See full
Cash & equivalents$22.7M-89.8%
Total debt$639.0K+539%
Total equity$185.8M-16.4%
Total assets$192.4M-14.9%

Cash flow

See full
Operating cash flow-$11.1M-1,571%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$87.17M—
Enterprise value$65.13M—

Returns & leverage

See full
Return on equity-22.9%-6.6pp
Debt / equity0×0.0×
Current ratio14.1×-46.3×

FAQ

When did Climb Bio, Inc. report Q2 2025 earnings?
Climb Bio, Inc. (CLYM) reported Q2 2025 earnings on August 12, 2025 before market open.
What were Climb Bio, Inc.'s Q2 2025 revenue and EPS?
Climb Bio, Inc. reported eps of $-0.13 for Q2 2025.
Did Climb Bio, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.19 by $0.06.
How did Climb Bio, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 92.8% from $-1.81.
Where can I find Climb Bio, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-106913) and the 10-Q periodic report (0000950170-25-106916) directly on SEC EDGAR. The filing index links above go to sec.gov.